Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Sikkerheds- og dosisfindingsundersøgelse af Neratinib hos børn og unge voksne med kræft, der er vendt tilbage eller ikke har reageret på behandling

2. november 2026 opdateret af: Memorial Sloan Kettering Cancer Center

En fase I/II undersøgelse af Neratinib hos pædiatriske patienter med recidiverende eller refraktære solide tumorer

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

14

Fase

  • Fase 2
  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T3B 6A8
        • Alberta Children'S Hospital
    • Arizona
      • Phoenix, Arizona, Forenede Stater, 85016
        • Phoenix Children'S Hospital
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72206
        • Arkansas Children's Hospital
    • California
      • Palo Alto, California, Forenede Stater, 94304
        • Stanford University School of Medicine and Stanford Cancer Institute
    • Florida
      • Orlando, Florida, Forenede Stater, 32806
        • Arnold Palmer Hospital for Children
    • New York
      • New York, New York, Forenede Stater, 10065
        • Memorial Sloan Kettering Cancer Center
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Pennsylvania State Hershey Children's Hospital
    • Texas
      • San Antonio, Texas, Forenede Stater, 78229
        • University of Texas
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84113
        • Huntsman Cancer Institue

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

3 år til 21 år (Barn, Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis: Pathologic confirmation of solid tumor, including central nervous system tumor or lymphoma.

  • Recurrent or Refractory Disease for which no further effective standard treatment is available.

  • Patient must have failed at least one prior therapy.

  • All patients must have evaluable disease as defined as:

    • Solid tumors must have a lesion evaluable by RECIST criteria version 1.1;
    • Central nervous system tumors will be evaluated by RANO criteria.
  • Available tissue to perform protein and genomic analysis

  • Age:

    • Phase 1: ≥ 3 and ≤ 21 years of age at time of enrollment
    • Phase 2: ≥ 3 and ≤ 21 years of age at diagnosis
  • Body Surface Area requirements varied by dose level:

Dose Level BSA (m2)

  • 1 ≥ 0.82

    1. ≥ 0.66
    2. ≥ 0.52
    3. ≥ 0.45
  • Performance level:

    • Lansky score ≥ 60% (patients < 16 years of age)
    • Karnofsky score ≥ 60% (patients ≥ 16 years of age)
  • Cardiac Function: Patients must have a shortening fraction ≥ 27% or left ventricular ejection fraction ≥ 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA).

  • Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential ≤ 7 days before starting neratinib therapy.

  • Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product. Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product.

  • Written informed consent/assent prior to any study-specific procedures.

  • Patient must be able to swallow tablet or have existing gastrostomy feeding tube to enable administration of tablet.

  • Patients must have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering this study.

Exclusion Criteria:

  • Prior treatment within the following timeframes:

    • Systemic chemotherapy or biologic therapy ≤ 2 weeks or 5 half lives (t ½) of the agent used, whichever is shorter, prior to the start of neratinib
    • Radiation therapy outside the central nervous system ≤ 14 days prior to neratinib
    • Radiation to the central nervous system ≤ 12 weeks prior to initiation of neratinib
  • Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:

    • 60 days from allogeneic SCT

      • Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD
  • Inadequate marrow function in Cohort 1:

    • Absolute neutrophil count < 1.0 x 10^9 /L
    • Platelets < 100 x 10^9 /L
    • Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
  • Total bilirubin > 1.5 X the upper limit of normal (ULN) for age

  • AST (SGOT) and ALT (SGPT) > 3 X ULN (unless attributed to disease involvement)

  • Serum creatinine > 1.5 X ULN for age or creatinine clearance ≤ 60mL/min/1.73m^2

  • Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days (or decreasing dose of corticosteroid) are eligible to participate in the study.) Patients with primary central nervous system tumors are eligible.

  • Clinically active cardiac disease, including prolonged QTc interval ≥ 481ms (i.e. ≥ grade 2)

  • Pregnant or breast-feeding women

  • Being actively treated for a concurrent malignancy with the exception of basal cell carcinoma or carcinoma in situ of the cervix.

  • Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, unexplained fever > 38.5°C (101.3°F) or psychiatric illness/social situation that would limit compliance with study requirements.

  • Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥ 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).

  • Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease

  • Known history of hepatitis C or known active hepatitis B infection

  • Known hypersensitivity to any component of the investigational product

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Neratinib

There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.

Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
the number of patients who have experienced Dose Limiting Toxicity
Tidsramme: 1 year

NCI CTCAE Version 4.0.Definition of Hematologic Dose-Limiting Toxicity (solid tumor cohort only) Any hematologic toxicity as indicated: Febrile neutropenia defined as Grade 3 or 4 neutropenia with fever ≥ 38.5°C and /or infection requiring antibiotic or antifungal treatment Grade 4 neutropenia lasting > 7 days Grade 4 thrombocytopenia lasting > 7days Any drug-related adverse experience, regardless of grade, leading to a dose reduction of a study drug. Non-Hematologic Dose-Limiting Toxicities: Non-hematologic dose-limiting toxicity will be defined as any Grade 3, 4 or 5 nonhematologic toxicity with the specific exception of: Any grade diarrhea that occurs in the setting of poor compliance with supportive measures that last for < 48 hours Any grade dehydration related to diarrhea that occurs in the setting of inadequate compliance to supportive care measures that last for < 48 hours.

1 year

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. oktober 2016

Primær færdiggørelse (Anslået)

1. oktober 2027

Studieafslutning (Anslået)

1. oktober 2027

Datoer for studieregistrering

Først indsendt

12. oktober 2016

Først indsendt, der opfyldte QC-kriterier

12. oktober 2016

Først opslået (Anslået)

13. oktober 2016

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 16-878

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .